784 Results
Sort By:
Published on April 9, 2020
The results of research by University of British Columbia scientists suggest that giving up smoking could lessen the chance that an infection with SARS-CoV-2 coronavirus will lead to severe COVID-19 disease. Their studies found that the lung cells of people who are current cigarette smokers, and individuals with chronic obstructive…
Published on April 7, 2020
An anti-parasitic drug that is available around the world stops SARS-CoV-2 coronavirus from replicating in cells within a couple of days, according to findings from in vitro studies by Monash University’s Biomedicine Discovery Institute (BDI), working with the Peter Doherty Institute of Infection and Immunity. BDI research lead Kylie Wagstaff,…
Published on April 6, 2020
Molecular diagnostics and assay development company Luminex announced today that its ARIES SARS-CoV-2 Assay for rapid detection of the virus that causes COVID-19 has received and Emergency Use Authorization from the FDA. According to the company, the test will run on its FDA-approved ARIES system an automated system that can…
Published on April 2, 2020
Researchers at Massachusetts Institute of Technology (MIT) have developed a nanoparticle-based approach that allows the early diagnosis of lung cancer through a simple urine test. The approach detects biomarkers resulting from the interaction of protein-coated nanoparticles with disease-associated peptides in the tumor microenvironment. Experiments in two different mouse models of…
Published on March 26, 2020
Artificial intelligence-drive health technology company Sophia Genetics, has announced it is extending its partnership with next-generation sequencing (NGS) assay development company Paragon Genomics, to provide a COVID-19 test offering that combines Paragon Genomics’ CleanPlex SARS-CoV-2 NGS panel reagent kit for whole-genome sequencing of the coronavirus with the advanced analytical power…
Published on March 26, 2020
The holy grail of the current pandemic—a vaccine for COVID-19—will not be available next month. It may not even be ready by next year. Regardless, the strides being made are happening at unprecedented speed. One of the companies at the front of the pack is Moderna Therapeutics. Synbiobeta, the network…
Published on March 19, 2020
Researchers at the Scripps Research Institute say their genetic analysis of SARS-CoV-2 coronavirus and related viruses has found no evidence that SARS-CoV-2 is the result of bioengineering in a lab. Rather, said Kristian Andersen, Ph.D., an associate professor of immunology and microbiology at Scripps Research and corresponding author of the…
Published on March 18, 2020
The virus that causes COVID-19, coronavirus disease 2019, stays “live” for several hours in aerosols, and for days on surfaces, according to a new study in the New England Journal of Medicine (NEJM). These findings suggest that people may acquire the virus through the air and after touching contaminated objects. The…
Published on March 16, 2020
Although some key aspects of how COVID-19 spreads are beginning to be determined, unanswered questions regarding transmission dynamics remain. One key question has been whether the virus can be spread by people before they start exhibiting symptoms. A new paper addresses this question and, although the conclusions are based on…
Published on March 13, 2020
For Trey Martin, the president of Integrated DNA Technologies (IDT), the last few weeks have been anything but typical at the Coralville, Iowa company. Indeed, IDT finds itself in the center of the COVID-19 outbreak response. When the outbreak reached the United States in February, the CDC and FDA reached…
Published on March 12, 2020
For patients admitted to the hospital and confirmed to have the new coronavirus disease (COVID-19), the key risk factors for death are: Advanced age Signs of sepsis Blood clotting issues These risk factors come from a new retrospective study that evaluated data records for 191 patients—137 survivors and 54 non-survivors.…
Published on March 11, 2020
A protein produced by the human immune system can potently inhibit several corona viruses, including the one behind the current COVID-19 outbreak, an international team of investigators reports. Their research reveals that the LY6E protein impairs the coronavirus’ ability to initiate infection, which could lead to treatments for the illness.…
Published on March 10, 2020
The Bill & Melinda Gates Foundation along with Wellcome and Mastercard are committing $125 million in seed funding to create an accelerator to expedite development of treatments for COVID-19. The COVID-19 Therapeutics Accelerator is designed to bring together resources and expertise to lower the financial and technical risk for academia,…
Published on February 25, 2020
Researchers at Harvard University and the Guangzhou Institute of Respiratory Health in China will partner to develop therapies designed to prevent new Coronavirus infections and treat existing ones, through a $115 million research collaboration funded by Chinese real estate giant China Evergrande Group. Investigators from Harvard Medical School led by…